

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 26, 2005

Elaine Willig

Elaine Willig

#3 PCT
JC03 Rec'd PCT/PTO 26 APR 2005



Attorney Docket No. CHM-006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
RICHARD A. LANG et al. :
Serial No.: 10/519,527 :
Filed: December 27, 2004 :
Title: In Vivo Angiogenesis Assay

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.56, 1.97 and 1.98
(WITHIN 3 MONTHS OF FILING OR PRIOR TO FIRST OFFICE ACTION)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.56, 1.97 and 1.98, Applicant request the Examiner to make of record the documents listed on the attached PTO/SB/08 form. Copies of the listed documents that are not U.S. patent documents are also enclosed. In accordance with MPEP 609, the Examiner is requested to initial each document listed on the attached PTO/SB/08 form in the space provided, make a copy of the initialed form, and return the copy to Applicants' attorney.

This submission does not represent that a search has been made or that no closer art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This paper and the enclosed documents are being submitted in accordance with 37 CFR 1.97(b), i.e., within three (3) months of the application filing date or prior to a first Office Action on the merits. Therefore, no fee is believed to be due.

Respectfully submitted,

For: Richard A. Lang

By




Daniel F. Nesbitt
Attorney for Applicant
Registration No. 33,746
(513) 229-0383
Customer Number 3 8 1 5 5

April 14, 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	10/519,527
Filing Date	December 27, 2004
First Named Inventor	Richard A. LANG et al.
Art Unit	
Examiner Name	
Attorney Docket Number	CHM-006

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
		US-	5,976,782	11/02/1999	Parish et al.	
		US-	6,329,348 B1	12/11/2001	Crystal et al.	
		US-	5,830,879	11/03/1998	Isner	
		US-	5,972,639	10/26/1999	Parandoosh	
		US-	6,133,231	10/17/2000	Ferrara et al.	
		US-	5,935,076	08/10/1999	Smith et al.	
		US-	6,302,850	10/16/2001	Tsukada, et al.	
		US-	6,305,804	10/23/2001	Rice, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 00/47107	08/17/2000	Pang, et al.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T ²
		BROWN, K.J. et al., A Novel In Vitro Assay for Human Angiogenesis, Lab Invest, Oct. 1996, 75(4), 539-55	
		MEESON, Annette, et al., A Relationship Between Apoptosis and Flow During Programmed Capillary Regression is Revealed by Vital Analysis, Development 122, (1996), pgs. 3929-3938, 1996, Great Britain	
		LOBOV, I.B., et al., Angiopoietin-2 Displays VEGF-Dependent Modulation of Capillary Structure and Endothelial Cell Survival In Vivo, PNAS, 08/20/2002, Vol. 99, No. 17, pgs. 11205-11210	
		LANG, R. et al., Apoptosis During Macrophage-Dependent Ocular Tissue Remodelling, Development 120, (1994), pgs. 3395-3403 (1994), Great Britain	
		LANG, R.A., Apoptosis In Mammalian Eye Development: Lens Morphogenesis, Vascular Regression and Immune Privilege, Cell Death and Differentiation (1997) 4, pgs. 12-20	
		ALIPRANTIS, A.O. et al., Do Macrophages Kill Through Apoptosis? Immunology Today, 12/1996, Vol. 17, No. 12, pgs. 573-576	
		LANG, R.A., et al., Macrophages are Required for Cell Death and Tissue Remodeling in the Developing Mouse Eye, Cell 08/13/1993, Vol. 74, pgs. 453-462,	
		DIEZ-ROUX, Graciana et al., Macrophages Induce Apoptosis in Normal Cells In Vivo, Development 124, (1997), pgs. 3633-3638, (1997), Great Britain	
		DIEZ-ROUX, Graciana et al., Macrophages Kill Capillary Cells in G ₁ Phase of the Cell During Programmed Vascular Regression, Development 126, (1999), pgs. 2141-2147, (1999), Great Britain	
		MEESON, Annette P., et al., VEGF Deprivation-Induced Apoptosis is a Component of Programmed Capillary Regression, Development 126, (1999), pgs. 1407-1415, (1999), Great Britain	
		YANAGAWA, Toshihiro, et al, Aqueous Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Decrease During Regression of Rabbit Pupillary Membrane, Japanese Journal of Ophthalmology, Volume 42, Issue 3, 05/06/1998, pgs. 157-161	Abstract
		ITO, M, et al., Regression of the Hyaloid Vessels and Pupillary Membrane of the Mouse, Anat Embryol (Berl), 1999 Oct.; 200(4): 403-11.	Abstract

Examiner Signature	Date Considered
--------------------	-----------------